NRx Pharmaceuticals (MUN:B1Q) - Stock Price, News & Analysis

B1Q Stock Overview

B1Q fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Rewards

Risk Analysis

Shares are highly illiquid

Negative shareholders equity

Earnings have declined by 0.03% per year over past 5 years

Makes less than USD$1m in revenue ($0)

+ 2 more risks

NRx Pharmaceuticals, Inc. Competitors

SynBiotic

DUSE:SBX

€44.5m

Apontis Pharma

XTRA:APPH

€69.0m

MPH Health Care

DB:93M1

€90.8m

Pierrel

DB:2FJ0

€92.8m

Price History & Performance

Summary of all time highs, changes and price drops for NRx Pharmaceuticals
Historical stock prices
Current Share Price	US$3.37
52 Week High	US$6.55
52 Week Low	US$2.80
Beta	1.03
1 Month Change	-32.64%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-98.25%

Recent updates

Shareholder Returns

	B1Q	DE Pharmaceuticals	DE Market
7D	14.1%	3.9%	2.0%
1Y	n/a	-28.2%	2.0%

Return vs Industry: Insufficient data to determine how B1Q performed against the German Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how B1Q performed against the German Market.

Price Volatility

Is B1Q's price volatile compared to industry and market?
B1Q volatility
B1Q Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	6.5%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	10.2%
10% least volatile stocks in DE Market	2.5%

Stable Share Price: B1Q's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine B1Q's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2015	n/a	Steve Willard	www.nrxpharma.com

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned FDA-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital.

NRx Pharmaceuticals, Inc. Fundamentals Summary

How do NRx Pharmaceuticals's earnings and revenue compare to its market cap?
B1Q fundamental statistics
Market cap	€34.49m
Earnings (TTM)	-€28.19m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-1.2x

P/E Ratio

Is B1Q overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
B1Q income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$30.16m
Earnings	-US$30.16m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-2.89
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	-78.1%

How did B1Q perform over the long term?

See historical performance and comparison

B1Q Stock Overview

Rewards

Risk Analysis

NRx Pharmaceuticals, Inc. Competitors

DUSE:SBX

€44.5m

XTRA:APPH

€69.0m

DB:93M1

€90.8m

DB:2FJ0

€92.8m

Price History & Performance

Recent News & Updates

NRx Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $2.0031 million.

NRx Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

NRx Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

NRx Pharmaceuticals, Inc. Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics

NRx Pharmaceuticals, Inc. Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)

NRx Pharmaceuticals, Inc. Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression

Recent updates

NRx Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $2.0031 million.

NRx Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

NRx Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

NRx Pharmaceuticals, Inc. Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics

NRx Pharmaceuticals, Inc. Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)

NRx Pharmaceuticals, Inc. Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression

NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing

NRx Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 28, 2024

Less than half of directors are independent

NRX Pharmaceuticals Announces Last Patient, Last Visit in Its Phase 2B/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression

NRx Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $1.5 million.

NRx Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $1.5 million.

Panel Grants NRx Pharmaceuticals Request for an Exception to Nasdaq Listing Rules Until April 16, 2024, to Demonstrate Compliance with the Rule

NRx Pharmaceuticals, Inc. Announces Completion of Enrollment of Its Phase 2b/3 Trial of NRx-101 in Suicidal Treatment Resistant Bipolar Depression

NRx Pharmaceuticals, Inc. Announces FDA Qualified Infectious Disease Product and Fast Track Designation of NRX-101 in Complicated Urinary Tract Infection and Pyelonephritis

NRx Pharmaceuticals Demonstrates Compliance with Nasdaq MVLS Standard

Nrx Pharmaceuticals Announces Election of Janet Rehnquist to Its Board of Directors

NRx Pharmaceuticals, Inc. Announces FDA Clearance of its Investigational New Drug (IND) Application for NRX-101 in the Treatment of Complicated Urinary Tract Infections

NRx Pharmaceuticals, Inc., Annual General Meeting, Dec 19, 2023

NRx Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 14, 2023

NRx Pharmaceuticals Announces Further Alignment with FDA on Initiation of Registrational Trials for NRX-101 in the Treatment of Chronic Pain

NRx Pharmaceuticals Receives Formal Notice from the Listing Qualifications Staff of Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

NRx Pharmaceuticals Announces Strategic Acceleration of its Plans to Develop Commercial Form of NRX-100 (intravenous ketamine) to Treat Acute Depression and Suicidality

NRx Pharmaceuticals Announces FDA Permission to Proceed on Investigational New Drug (IND) Application for NRX-101 to Treat Chronic Pain

NRX Pharmaceuticals, Inc. Appoints Richard Narido, as Principal Financial Officer and Principal Accounting Officer

NRx Pharmaceuticals, Inc. Announces New Data That Demonstrates Potent in Vitro Activity of NRx-101

NRx Pharmaceuticals Announces Submission of an Investigational New Drug Application for NRX -101 in the Treatment of Chronic Pain

NRx Pharmaceuticals, Inc. announced that it expects to receive $1.2 million in funding

NRx Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 14, 2023

NRx Pharmaceuticals Receives Written Notification from Nasdaq Regarding Non-Compliance with Nasdaq Listing Rule 5450(b)(2)(A) – Market Value of Listed Securities

NRx Pharmaceuticals, Inc. Reports Minutes of U.S. Food and Drug Administration Meeting on Development of NRX-101 to Treat Severe Bipolar Depression in Patients with Suicidality

NRx Pharmaceuticals, Inc. Provides Progress Update on Interactions with the FDA regarding Path to NDA Submission for NRX-101

NRx Pharmaceuticals, Inc. Initiates Phase 3 Trial Treating Patients with Bipolar Depression with Acute Suicidality - First Clinical Site Contracted

Relief Therapeutics Holding AG (SWX:RLF) acquired ZYESAMI of NRx Pharmaceuticals, Inc.

Relief Therapeutics Holding AG and NRx Pharmaceuticals, Inc. Announces Close of Definitive Settlement Agreements

NRx Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

NRx Pharmaceuticals, Inc. Produces First Phase 3-stage NRX-101 Drug Made Using Commercial Process

NRx Pharmaceuticals, Inc. announced that it has received $10 million in funding

NRx Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 15, 2022

NRx Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

NRx Pharmaceuticals, Inc. Announces the Appointment of Stephen Willard as its Chief Executive Officer

Nrx Pharmaceuticals, Inc. Announces FDA Declines Emergency Use Authorization for Zyesami® (Aviptadil) for Subgroup of Patients with Critical Covid-19 At Immediate Risk of Death from Respiratory Failure Despite Treatment with Approved Therapy, Including Remdesivir

High number of new and inexperienced directors

NRx Pharmaceuticals, Inc. Announces Class Action Suit Against the Company Dismissed

Nrx Pharmaceuticals, Inc. Announces Director Resignation

NRx Pharmaceuticals, Inc., Annual General Meeting, Jul 18, 2022

NRx Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Denied for aviptadil

NRx Pharmaceuticals, Inc. Provides Update on Breakthrough Therapy Designation Request for ZYESAMI® (Aviptadil)

NRx Pharmaceuticals Appoints Seth Van Voorhees as Chief Financial Officer, Effective June 13, 2022

Co-Founder recently bought €54k worth of stock

NRx Pharmaceuticals, Inc. Announces Executive Changes

NRx Pharmaceuticals, Inc. Announces Data Safety Monitoring Board (DSMB) Update on U.S. National Institutes of Health (NIH) Study of ZYESAMI® (aviptadil) in Critical COVID-19

High number of new and inexperienced directors

Shareholder Returns

Price Volatility

About the Company

NRx Pharmaceuticals, Inc. Fundamentals Summary

0.0x

-1.2x